Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

A decade from now, considering Vertex's pipeline, the company could potentially offer a treatment ... It focuses on a very ...

Pain is an area with limited treatment options ... Last year’s Alpine acquisition added povetacicept to Vertex’s pipeline, which Vertex believes has a “pipeline in a product” potential.

Merck should be a useful partner for these, since it already has three oncology drugs on the market and eight in clinical trials in its pipeline. Journavx, Vertex’s nonopioid pain-signal ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals ... and much of that attributed to pipeline and pain opportunity, RBC remains ...